BMS, AstraZeneca diabetes pill wins US panel backing, though risks highlighted
This article was originally published in Scrip
Executive Summary
The benefits of Bristol-Myers Squibb and AstraZeneca’s diabetes pill dapagliflozin outweigh potential risks, a panel of US FDA advisers decided.